&nbsp;

Oct 2023

Drug

IDArubicin

Other Name(s): Idamycin®

Quick Link(s):

Oct 2023

Drug

iBRUtinib

Other Name(s): Imbruvica®

Quick Link(s):

Feb 2023

Drug

daratumumab

Other Name(s): Darzalex®

Quick Link(s):

Jan 2023

Regimen

DOXO

Cancer Type:

Gynecologic,

Endometrial

Intent: Palliative

Drugs Used:

Quick Link(s):

Regimen Monograph

Oct 2023

Regimen

DOXO

Cancer Type:

Gynecologic,

Uterine Sarcoma,

Sarcoma,

Soft Tissue,

Uterine

Intent: Adjuvant, Palliative

Drugs Used:

Quick Link(s):

Regimen Monograph

Oct 2023

Regimen

DOXO

Cancer Type:

Breast

Intent: Palliative

Drugs Used:

Quick Link(s):

Regimen Monograph

Oct 2023

Regimen

DEXAPOMA

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

Exceptional Access Program

pomalidomide - For patients with relapsed and/or refractory multiple myeloma, according to specific criteria.

ODB - General Benefit

dexamethasone

Drugs Used:

pomalidomide,

dexamethasone

Quick Link(s):

Regimen Monograph

Apr 2023

Regimen

IBRU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - For relapsed and refractory Mantle Cell Lymphoma, according to clinical criteria

Drugs Used:

iBRUtinib

Quick Link(s):

Regimen Monograph

Feb 2023

Regimen

DOXO

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Palliative

Drugs Used:

Quick Link(s):

Regimen Monograph

Oct 2023

Regimen

IBRU

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - For patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to specific criteria.

Drugs Used:

iBRUtinib

Quick Link(s):

Regimen Monograph

Feb 2023

Regimen

DHAP

Cancer Type:

Hematologic,

Lymphoma - Hodgkin,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Curative

Funding:

ODB - General Benefit

dexamethasone

Drugs Used: